New Rochelle, NY, December 2, 2013–The Genetics Policy Institute (GPI) will bestow its 2013 Education Award on Mary Ann Liebert, President and CEO of the company that bears her name, citing her work in educating patients, researchers, and the broader stem cell community, and in raising the standard in medical research journalism. Ms. Liebert is the president and CEO of Mary Ann Liebert, Inc., a media empire known for establishing authoritative peer-reviewed journals in promising areas of science and biomedical research. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), debuted in 1980, was the first in its field, and is today the industry’s most widely read publication worldwide. Stem Cells and Development is an authoritative peer-reviewed journal dedicated to developments in the biology, characteristics, and therapeutic utility of stem cells. Many journals she publishes intersect the field of regenerative medicine, contributing to the scholarship and advancing stem cell science. Ms. Liebert is also the founder and executive vice president of the Rosalind Franklin Society, which recognizes and advances important contributions made by women in the life sciences.
- Could platelet-rich plasma injections help avoid knee surgery? More studies may give answer.
- An Experiment Using Human Stem Cells Ended Up Reversing Diabetes in Mice
- Stem Cell Therapy Reduces Need for Nearly 10% of Hip Replacements
- New therapy harnesses “dancing molecules” to reverse paralysis, repair tissue after spinal cord injuries
- Woman Hopes Father She’s Never Met Will Save Her Life by Donating Bone Marrow
- RNA Control Switch: Engineers Devise a Way To Selectively Turn On Gene Therapies in Human Cells
- Hoag trial spells hope for patients battling aggressive form of breast cancer
- Decades of research show common stem cells could fuel advances in regenerative medicine
- Nerve Repair with Help From Stem Cells
- Breakthrough within reach for diabetes scientist and patients nearest to his heart
- Neurona Therapeutics Receives IND Clearance to Initiate Phase 1/2 Clinical Trial of Neural Cell Therapy NRTX-1001 in Chronic Focal Epilepsy Patients
- Researcher awarded $12 million for a stem cell trial to improve outcomes of young blood cancer patients
- Stem cell therapy for kidney damage repair
- Takeda Receives Approval to Manufacture and Market Alofisel®▼ (darvadstrocel) in Japan for Treatment of Complex Perianal Fistulas in Patients with Non-active or Mildly Active Luminal Crohn’s Disease
- Repeated injury to airway stem cells could be major factor in chronic lung disease